Saudi Arabia (KSA) sits at a unique historical moment. Petroleum revenues propelled the Middle Eastern nation to become one of the world’s wealthiest, but the Kingdom’s current ambitions extend far beyond oil.
As part of its overarching ‘Saudi Vision 2030’ economic diversification plan, Saudi is aiming to play a much greater regional and global role in everything from artificial intelligence to sport and, significantly, healthcare.
Central to this transformation is the role of the private sector, which is actively contributing to the development of both the infrastructure and technological advancements needed to elevate healthcare standards.
In parallel, Saudi Arabia’s local pharmaceutical manufacturers are making concerted efforts to move up the value chain, developing proprietary formulations and producing essential medicines and vaccines domestically.
This push not only strengthens the country's healthcare sector but also enhances its medicinal sovereignty, reducing reliance on imports and ensuring a more self-sufficient healthcare ecosystem.
As KSA rapidly evolves into a healthcare hub in the Middle East, it offers significant opportunities for global pharmaceutical and life sciences companies to enter and grow within this dynamic market.
Saudi Pharmaceutical Market: The Shift From Generics To Innovation
For decades, Saudi Arabia’s pharmaceutical industry was centered around generic drugs—affordable alternatives to brand-name medications. These generics have provided essential healthcare solutions to the population and helped build a robust manufacturing infrastructure.
However, as healthcare needs have evolved, especially with the rise of complex and chronic conditions, the limitations of a generics-based strategy have become evident. To address these challenges, the Kingdom is now focusing on pharmaceutical innovation and R&D, aiming to offer advanced, personalized therapeutic solutions that align with global healthcare trends.
Driving Factors: Saudi Vision 2030 and Economic Diversification
Vision 2030 is the cornerstone of this transformation. The initiative (see Health Sector
Transformation Program 2021-2025) seeks to reduce the Kingdom’s dependence on oil revenues by fostering the growth of other industries, including pharmaceuticals. Key goals include enhancing drug security, increasing domestic manufacturing, and attracting foreign investment into the life sciences sector.
By boosting domestic production and reducing reliance on imports, Saudi Arabia is strengthening its pharmaceutical supply chain and protecting itself against global supply disruptions.
This focus on drug security is essential for ensuring that the nation has access to essential medications, even during global crises. The Kingdom is investing heavily in research institutions, education, and healthcare infrastructure to support pharmaceutical innovation.
Establishing advanced research facilities, fostering public-private partnerships, and attracting foreign companies to set up local manufacturing plants are key strategies in achieving these goals.
NUPCO: A Catalyst for Local Manufacturing
A pivotal player in the Kingdom’s pharmaceutical landscape is NUPCO (the National Unified Procurement Company), which plays a significant role in promoting local production. Established to streamline the procurement of healthcare supplies for public health facilities, NUPCO’s mission is to ensure an efficient supply of medical products, services, and equipment across the Kingdom.
NUPCO has introduced innovative procurement strategies designed to increase domestic pharmaceutical manufacturing. One of the most significant initiatives is the provision of offtake agreements, which guarantee the purchase of locally produced drugs and medical products. This provides pharmaceutical companies with a secure and stable market for their products, encouraging them to invest in local manufacturing facilities.
Starting in 2024, NUPCO’s tender processes will prioritize companies with regional headquarters in Saudi Arabia, further incentivizing multinational pharmaceutical firms to localize their production in the Kingdom. By ensuring guaranteed contracts, NUPCO has become a cornerstone in Saudi Arabia’s push to shift from a reliance on imported medicines to homegrown manufacturing.
“A contract with NUPCO is significant, as we purchase medicines and medical devices on behalf of the roughly 31 million Saudi citizens and public sector workers,” explains the agency’s CEO, Fahad Al Shebel.
And, in addition to the prize of a national guaranteed contract, foreign entities that increase local production will be able to negotiate higher drug prices and to distribute and sell pharmaceuticals within the country themselves, whereas imported pharmaceuticals can only be distributed through a Saudi company.
There are several additional benefits for companies that engage in local manufacturing, including inclusion on mandatory procurement lists and tendering advantages. Under procurement law, NUPCO grants a 10% price preference to local manufacturers. This means that if a local product’s price is within 10% of the lowest offer, it is considered the lowest bid, incentivizing purchases from local producers.
Beyond manufacturing, companies that make a long-term commitment to the Kingdom—such as relocating their regional headquarters, investing significantly in local clinical research, or employing a high percentage of Saudi nationals—receive substantial benefits.
As of 2024, only life sciences companies with regional headquarters in Saudi Arabia, or those granted exception status, are eligible to submit proposals for NUPCO tenders. Essentially, without establishing a local presence and embracing local content, companies risk being excluded from a large portion of the market.
Technology Transfer and Strategic Partnerships
Localization in Saudi Arabia is not just about manufacturing, but also acquiring the latest technology and expertise from global leaders in the pharmaceutical industry. Technology transfer agreements allow local companies to integrate advanced research, development, and manufacturing capabilities into their operations.
For example, companies like Sudair Pharmaceutical have forged partnerships with international giants such as Novartis and Dr. Reddy’s to transfer knowledge and enhance production capabilities. These partnerships benefit both Saudi firms, which gain valuable R&D insights, and multinational companies, which gain access to the local market under favorable conditions provided by Vision 2030.
French pharma Sanofi, and Danish specialty diabetes player Novo Nordisk have also for their part each benefited from seven-year offtake agreements for their decisions to localize insulin manufacturing, while Baxter has gained directly from its status as owner of the sole in-country manufacturing site for peritoneal dialysis products.
Pfizer and GSK are also examples of companies that have expanded their regional manufacturing facilities under the Vision 2030 framework. Pfizer invested USD 50 million to establish a state-of-the-art facility, while GSK continues to localize its production and R&D efforts to meet local demand. These investments not only advance Saudi Arabia’s pharmaceutical industry but also contribute to the overall economic diversification and growth of the nation.
Regulatory Reforms in Saudi Pharmaceutical Market
The Saudi Food and Drug Authority is playing a key role in driving innovation by modernizing regulatory frameworks and expediting drug approval processes.
By adopting international standards, such as those set by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the SFDA ensures that new pharmaceutical products meet the highest quality and safety standards. This regulatory environment is designed to attract biotech and pharmaceutical companies eager to introduce new, innovative therapies to the Saudi market.
Saudi Arabia is also making significant strides in clinical research, with government initiatives encouraging clinical trials to be conducted locally. With improved intellectual property protection and favorable regulatory reforms, the Kingdom is positioning itself as an attractive hub for pharmaceutical innovation in the MENA region.
Supporting Digital Transformation in Healthcare
Saudi Arabia is embracing the digital revolution in healthcare as part of its Vision 2030 agenda. The government has allocated USD 1.5 billion towards the digital transformation of the healthcare sector, focusing on telemedicine, e-Health, and other digital health initiatives.
These efforts aim to provide better access to healthcare services across the Kingdom and improve patient outcomes, particularly in the management of chronic diseases such as diabetes and cardiovascular conditions.
Mobile screening devices for cancer and other chronic diseases, along with awareness campaigns, are part of the government’s strategy to enhance preventative healthcare. Digital health solutions like telemedicine are also being integrated into the broader healthcare system, allowing for more efficient patient management and diagnosis.
What's next for Saudi's Pharmaceutical Sector
The pharmaceutical market in Saudi Arabia accounts for 37% of the broader MENA market, with projected annual sales expected to reach between USD 8.5 and 10.7 billion by 2032.
According to Invest Saudi, the pharmaceutical sector is expected to grow at a compound annual growth rate (CAGR) of 5.7% by 2030, with some projections as high as 9.6% by 2033.
The localization of drug manufacturing will generate high-value jobs, increase R&D capabilities, and attract significant foreign inves tments, all while ensuring a more stable supply of essential medicines.
Key Takeaways
Vision 2030 is reshaping Saudi Arabia's pharmaceutical sector, moving it from a reliance on generics toward innovation, and R&D.
The National Unified Procurement Company (NUPCO) plays a major role in promoting Saudi's pharmaceutical production through guaranteed offtake agreements, reducing reliance on imports and encouraging domestic manufacturing.
Saudi Arabia is actively pursuing strategic partnerships and technology transfer agreements with global pharmaceutical companies to localize advanced drug production and R&D capabilities within the Kingdom.
Regulatory reforms by the Saudi Food and Drug Authority (SFDA) are streamlining drug approval processes and fostering local manufacturing and clinical research efforts.
The country's digital healthcare transformation, driven by investments in telemedicine and e-Health solutions, is enhancing healthcare access and supporting the management of chronic diseases.
The Saudi pharmaceutical market is projected to experience robust growth, with a compound annual growth rate (CAGR) between 5.7% and 9.6% by 2033, positioning Saudi Arabia as a leading player in the MENA region.
With its strategic investments, regulatory advancements, and emphasis on local production, KSA is emerging as a pharmaceutical powerhouse in the Middle East and a key global player in life sciences.
If you are looking to capitalize on these opportunities, Outbound Pharma is your trusted partner, providing expert market intelligence, distributor identification, commercial advisory, and partnership facilitation to ensure a successful and sustainable market entry. Meet us at CPHI Middle East on December 10-12th, 2024 to discuss how we can support your growth in the region.
Claudio Rota, Ph.D.
Chief Executive Officer
Outbound Pharma
Comments